Table 2.
Primary endpoint and cause analysis
| HFNC | NIV | Risk difference, % (95% CI) | P value | |
|---|---|---|---|---|
| Treatment failure, n (%) | ||||
| Intention-to-treat analysis | 29/113 (25.7) | 16/112 (14.3) | 11.38 (0.25 ~ 21.20) | 0.033 |
| Per-protocol analysis | 28/110 (25.5) | 15/109 (13.8) | 11.69 (0.48 ~ 22.60) | 0.029 |
| Analysis of treatment failure, n (%) | ||||
| Aggravation of respiratory distress | 9/29 (31.0) | 6/16 (37.5) | -6.47 (-37.06 ~ 22.64) | 0.660 |
| Aggravation of hypoxemia | 7/29 (24.1) | 4/16 (25.0) | -0.86 (-31.41 ~ 25.68) | 0.949 |
| Aggravation of carbon dioxide retention | 13/29 (44.8) | 6/16 (37.5) | 7.33 (-24.74 ~ 35.94) | 0.373 |
HFNC High flow nasal cannula oxygen therapy; NIV on-invasive ventilation